KERX Share Price

Open 7.44 Change Price %
High 7.56 1 Day -0.02 -0.27
Low 7.37 1 Week 0.36 5.09
Close 7.43 1 Month 0.75 11.23
Volume 842648 1 Year -0.03 -0.40
52 Week High 8.38
52 Week Low 4.03
KERX Important Levels
Resistance 2 7.61
Resistance 1 7.53
Pivot 7.45
Support 1 7.33
Support 2 7.25
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
DCTH 0.14 -6.67%
BBEP 0.12 0.00%
More..
NASDAQ USA Top Gainers Stocks
SCHS 0.05 66.67%
CPSL 0.14 55.56%
LOCM 0.09 50.00%
HAUP 0.10 42.86%
SYMX 0.50 38.89%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
OPNT 11.40 24.73%
IFON 0.61 24.49%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
DCIX 0.19 -58.70%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX)

KERX Technical Analysis 4
As on 26th Jul 2017 KERX Share Price closed @ 7.43 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 5.75 & Buy for SHORT-TERM with Stoploss of 6.85 we also expect STOCK to react on Following IMPORTANT LEVELS.
KERX Target for July
1st Target up-side 8.2
2nd Target up-side 8.88
3rd Target up-side 9.56
1st Target down-side 6.26
2nd Target down-side 5.58
3rd Target down-side 4.9
KERX Other Details
Segment EQ
Market Capital 169714688.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.keryx.com
KERX Address
KERX
750 Lexington Avenue
20th Floor
New York, NY 10022
United States
Phone: 212-531-5965
Fax: 212-531-5961
KERX Latest News
Interactive Technical Analysis Chart Keryx Biopharmaceuticals, Inc. ( KERX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Keryx Biopharmaceuticals, Inc.
KERX Business Profile
Keryx Biopharmaceuticals, Inc. (Keryx) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and renal disease. The Company is developing KRX-0401, an oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, and also affects a number of other key signal transduction pathways, including the Jun N-terminal kinases pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and survival. KRX-0401 is in Phase III clinical development for both refractory advanced colorectal cancer and relapsed / refractory multiple myeloma, and in Phase I and Phase II clinical development for other tumor types. It is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes.